Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome

Acute coronary syndrome - rivaroxaban [ID532]: equality impact assessment - guidance review (PDF 161 KB)

Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination  information

Acute coronary syndrome - rivaroxaban [ID532]: final appraisal determination document (PDF 420 KB)

Acute coronary syndrome - rivaroxaban [ID532]: committee papers information

Acute coronary syndrome - rivaroxaban [ID532]: committee papers (PDF 982 KB)

Acute coronary syndrome - rivaroxaban [ID532]: consultation

Acute coronary syndrome - rivaroxaban [ID532]: consultation document (PDF 414 KB)

Acute coronary syndrome - rivaroxaban [ID532]: supporting information information

Acute coronary syndrome - rivaroxaban [ID532]: supporting information (PDF 14.41 MB)

Acute coronary syndrome - rivaroxaban: appendix B - final scope (PDF 97 KB)

Acute coronary syndrome - rivaroxaban: appendix C - final matrix (PDF 296 KB)

Acute Coronary Syndrome - rivaroxaban: NICEs response to consultee and commentator comments on provisional matrix (updated) (PDF 253 KB)

Acute coronary syndrome - rivaroxaban: equality impact assessment - scoping (PDF 45 KB)

Acute coronary syndrome - rivaroxaban: appendix C - provisional matrix (pre-referral) - November 2011 (PDF 61 KB)

Acute coronary syndrome - rivaroxaban: appendix B - draft scope for consultation (pre-referral) - November 2011 (PDF 59 KB)

Acute coronary syndrome - rivaroxaban: appendix C - provisional matrix (pre-referral) - November 2011 (PDF 61 KB)

Acute coronary syndrome - rivaroxaban: appendix B - draft scope for consultation (pre-referral) - November 2011 (PDF 59 KB)